Liraglutide Attenuates Non-Alcoholic Fatty Liver Disease in Mice by Regulating the Local Renin-Angiotensin System

The renin angiotensin aldosterone system and its therapeutic targets

(2019) Katrina M. Mirabito Colafella et al.   EXPERIMENTAL EYE RESEARCH

The softness of tumour-cell-derived microparticles regulates their drug-delivery efficiency

(2019) Qingle Liang et al.   Nature Biomedical Engineering

Glucagon-like peptide 1 (GLP-1)

(2019) T.D. Müller et al.   Molecular Metabolism

Pathways of hepatic and renal damage through non‐classical activation of the renin‐angiotensin system in chronic liver disease

(2019) Giovanni Sansoè et al.   LIVER INTERNATIONAL

Simultaneous angiotensin receptor blockade and glucagon‐like peptide‐1 receptor activation ameliorate albuminuria in obese insulin‐resistant rats

(2019) Ruben Rodriguez et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Liraglutide Improves Non-Alcoholic Fatty Liver Disease In Diabetic Mice By Modulating Inflammatory Signaling Pathways

(2019) Ying Luo et al.   Drug Design Development and Therapy

FGF21 Prevents Angiotensin II-Induced Hypertension and Vascular Dysfunction by Activation of ACE2/Angiotensin-(1–7) Axis in Mice

(2018) Xuebo Pan et al.   Cell Metabolism

Activation of ACE2/angiotensin (1–7) attenuates pancreatic β cell dedifferentiation in a high-fat-diet mouse model

(2018) Xiuping Xuan et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

GLP-1 receptor agonists stimulate ANGPTL8 production through the PI3K/Akt pathway in a GLP-1 receptor-dependent manner

(2018) Junling Liu et al.   PEPTIDES

Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)

(2018) Francesco Bifari et al.   PHARMACOLOGICAL RESEARCH

Liraglutide Enhances the Activity of the ACE-2/Ang(1–7)/Mas Receptor Pathway in Lungs of Male Pups from Food-Restricted Mothers and Prevents the Reduction of SP-A

(2018) J. Fandiño et al.   International Journal of Endocrinology

Exercise training modulates the hepatic renin-angiotensin system in fructose-fed rats

(2017) Eliete Dalla Corte Frantz et al.   EXPERIMENTAL PHYSIOLOGY

High glucose augments angiotensinogen in human renal proximal tubular cells through hepatocyte nuclear factor-5

(2017) Juan Wang et al.   PLoS One

Treatment of nonalcoholic fatty liver disease: role of AMPK

(2016) Brennan K. Smith et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Renin–angiotensin system inhibitors and fibrosis in chronic liver disease: a systematic review

(2016) Gaeun Kim et al.   Hepatology International

C/EBP homologous protein modulates liraglutide-mediated attenuation of non-alcoholic steatohepatitis

(2016) Khalidur Rahman et al.   LABORATORY INVESTIGATION

Lipid disorder and intrahepatic renin-angiotensin system activation synergistically contribute to non-alcoholic fatty liver disease

(2016) Yu Wu et al.   LIVER INTERNATIONAL

Angiotensin-converting enzyme 2/angiotensin-(1–7)/Mas axis activates Akt signaling to ameliorate hepatic steatosis

(2016) Xi Cao et al.   Scientific Reports

Preservation of Glucagon-Like Peptide-1 Level Attenuates Angiotensin II-Induced Tissue Fibrosis by Altering AT1/AT2 Receptor Expression and Angiotensin-Converting Enzyme 2 Activity in Rat Heart

(2015) Li-Hui Zhang et al.   CARDIOVASCULAR DRUGS AND THERAPY

Dipeptidyl Peptidase-4 Inhibition Ameliorates Western Diet–Induced Hepatic Steatosis and Insulin Resistance Through Hepatic Lipid Remodeling and Modulation of Hepatic Mitochondrial Function

(2015) Annayya R. Aroor et al.   DIABETES

Bedtime ingestion of hypertension medications reduces the risk of new-onset type 2 diabetes: a randomised controlled trial

(2015) Ramón C. Hermida et al.   DIABETOLOGIA

Activation of the GLP-1 Receptor by Liraglutide Increases ACE2 Expression, Reversing Right Ventricle Hypertrophy, and Improving the Production of SP-A and SP-B in the Lungs of Type 1 Diabetes Rats

(2015) Marina Romaní-Pérez et al.   ENDOCRINOLOGY

Exendin-4 alleviates angiotensin II-induced senescence in vascular smooth muscle cells by inhibiting Rac1 activation via a cAMP/PKA-dependent pathway

(2014) Liang Zhao et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

The angiotensin-converting enzyme 2/angiotensin (1–7)/Mas axis protects the function of pancreatic β cells by improving the function of islet microvascular endothelial cells

(2014) CHUN-LI LU et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Protective Action of Liraglutide in Beta Cells Under Lipotoxic Stress Via PI3K/Akt/FoxO1 Pathway

(2014) Shiying Shao et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Exendin-4 regulates lipid metabolism and fibroblast growth factor 21 in hepatic steatosis

(2014) Jinmi Lee et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

GLP-1(28–36) improves β-cell mass and glucose disposal in streptozotocin-induced diabetic mice and activates cAMP/PKA/β-catenin signaling in β-cells in vitro

(2013) Weijuan Shao et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes

(2013) Katsutoshi Miyagawa et al.   Cardiovascular Diabetology

Oral Formulation of Angiotensin-(1–7) Improves Lipid Metabolism and Prevents High-Fat Diet–Induced Hepatic Steatosis and Inflammation in Mice

(2013) John David Feltenberger et al.   HYPERTENSION

Glucagon-Like Peptide-1 (GLP-1): Effect on Kidney Hemodynamics and Renin-Angiotensin-Aldosterone System in Healthy Men

(2013) Jeppe Skov et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

GLP-1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c-JNK

(2013) Lili Zhang et al.   LIVER INTERNATIONAL

Oral Angiotensin-(1–7) prevented obesity and hepatic inflammation by inhibition of resistin/TLR4/MAPK/NF-κB in rats fed with high-fat diet

(2013) Sérgio Henrique Sousa Santos et al.   PEPTIDES

Up-regulation of components of the renin–angiotensin system in liver fibrosis in the rat induced by CCL4

(2013) Wei Zhang et al.   RESEARCH IN VETERINARY SCIENCE

Angiotensin 1-7 as Means to Prevent the Metabolic Syndrome: Lessons From the Fructose-Fed Rat Model

(2012) Y. Marcus et al.   DIABETES

Angiotensin Receptor Blockade Recovers Hepatic UCP2 Expression and Aconitase and SDH Activities and Ameliorates Hepatic Oxidative Damage in Insulin Resistant Rats

(2012) Priscilla Montez et al.   ENDOCRINOLOGY

Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A

(2012) Yuji Ishibashi et al.   MICROVASCULAR RESEARCH

Decreased hepatic gluconeogenesis in transgenic rats with increased circulating angiotensin-(1-7)

(2012) Victor Bilman et al.   PEPTIDES

The Mas receptor mediates modulation of insulin signaling by angiotensin-(1–7)

(2012) Marina C. Muñoz et al.   REGULATORY PEPTIDES

Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet

(2011) Jamie E. Mells et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Liver lipid content is reduced in rat given 7-day administration of angiotensin II

(2011) Nobukazu Ishizaka et al.   JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM

Glucagon-like peptide–1 and candesartan additively improve glucolipotoxicity in pancreatic β-cells

(2011) Hong-Wei Wang et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Angiotensin AT1 receptor activation mediates high glucose-induced epithelial-mesenchymal transition in renal proximal tubular cells

(2010) Li Zhou et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway

(2010) Nitika Arora Gupta et al.   HEPATOLOGY

Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase

(2010) Shani Ben-Shlomo et al.   JOURNAL OF HEPATOLOGY

Oxidative Stress-Mediated Mitochondrial Dysfunction Contributes to Angiotensin II-Induced Nonalcoholic Fatty Liver Disease in Transgenic Ren2 Rats

(2009) Yongzhong Wei et al.   AMERICAN JOURNAL OF PATHOLOGY

Losartan reduces liver expression of plasminogen activator inhibitor-1 (PAI-1) in a high fat-induced rat nonalcoholic fatty liver disease model

(2009) Maria Soledad Rosselli et al.   ATHEROSCLEROSIS

Angiotensin-(1–7), an alternative metabolite of the renin–angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat

(2009) John S. Lubel et al.   CLINICAL SCIENCE

Editorial [Hot Topic: Novel Peptides and Proteins in Diabetes Mellitus (Guest Editors: Po Sing Leung and Marc de Gasparo)]

(2009) Po Leung et al.   CURRENT PROTEIN & PEPTIDE SCIENCE

GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice

(2009) M. H. Noyan-Ashraf et al.   DIABETES

Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance

(2008) A. P. Jayasooriya et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA